Discoveries to Change Lives.
The worrying and increasing development of bacterial
resistance has led to the search of alternative substances
to antibiotics. One of them is the application of phage-encoded
lytic proteins, known as enzybiotics, on which our company is focused.
Telum Therapeutics SL is a global drug discovery biotechnology
company specializing in the use of Engineered Phage Lytic
Proteins as new antimicrobial products.
Numerous studies place the bacteriophages and, specially, their lytic enzymes, as one of the most promising alternatives to the traditional
antibiotics. For this reason, Telum Therapeutics is creating a broad bacteria and phage collection from anthropogenic and cave explorations to obtain new bacteriophages and lytic enzymes with potential antibacterial therapeutic purposes.
Telum’s mission in the field of antibiotic drug development is to give hope to patients suffering with drug resistant infections by developing new antimicrobial agents.
APEXp® under Trade secret protection
Advanced Phage Enzybiotics from exploration platform
02
03
04
05
06
07
08
01
Sample collection
02
APEXp® Under Trade Secret
03
APEXp® Under Trade Secret
04
APEXp® Under Trade Secret
05
Protein Engineering
06
High throughput screening
07
Secondary Modifications
08
Select Leading Candidates
APExTM
Advance Phage Enzybiotics from
exploration platform.
Telum Therapeutics Development Pipeline
Within our pipeline we have specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa
Candidate Name
Target Pathogen
Indication
Rights
Confidential
Acinetobacter baumannii, including CRAB
HABP/VABP
Fully-owned
Candidate Name
Confidential
Target Pathogen
Acinetobacter baumannii, including CRAB
Indication
HABP/VABP
Rights
Fully-owned
Candidate Name
Target Pathogen
Indication
Rights
Confidential
Staphylococcus aureus MRSA
Prosthetic Joint Infection (PJI) and cardiac implantable electronic device (CIED)
Fully-owned
Candidate Name
Confidential
Target Pathogen
Staphylococcus aureus MRSA
Indication
Prosthetic Joint Infection (PJI) and cardiac implantable electronic device (CIED)
Rights
Fully-owned
Candidate Name
Target Pathogen
Indication
Rights
Confidential
Enterococcus faecium VRE
Nosocomial infections
Fully-owned
Candidate Name
Confidential
Target Pathogen
Enterococcus faecium VRE
Indication
Nosocomial infections
Rights
Fully-owned